Viracta Therapeutics (FRA:RYI) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Viracta Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was €-6.39 Mil. Viracta Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Viracta Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Viracta Therapeutics's current FCF Yield % is -518.34%.

The historical rank and industry rank for Viracta Therapeutics's FCF Margin % or its related term are showing as below:

FRA:RYI's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -135.76
* Ranked among companies with meaningful FCF Margin % only.

Viracta Therapeutics FCF Margin % Historical Data

The historical data trend for Viracta Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics FCF Margin % Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Viracta Therapeutics's FCF Margin %

For the Biotechnology subindustry, Viracta Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's FCF Margin % falls into.

Viracta Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Viracta Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-36.708	/	0
	=	%

Viracta Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-6.391	/	0
	=	%

Viracta Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.